+86 592 5365887
1.Vidarabine has anti-herpes simplex virus HSV-1 and HSV-2 effects for the treatment of herpes simplex meningitis, as well as for herpes zoster and varicella infection in immunosuppressed patients. But it is not effective against cytomegalovirus. The monophosphate of this product has the effect of inhibiting the replication of hepatitis B virus. When the dose is above 10 mg/kg per day, anorexia, nausea, vomiting, diarrhea, elevated transaminases, dizziness, fatigue, etc. may occur. A small number can also have myelosuppression, mainly manifested by white blood cells and thrombocytopenia. Vidarabine has teratogenic effects and is contraindicated in pregnant women. Breast milk, infants, and liver and kidney dysfunction should be used with caution.
2.Vidarabine treatment of chronic hepatitis B, herpes simplex encephalitis, herpes zoster, genital herpes, neonatal herpes simplex infection, chickenpox in immunodeficiency patients, herpes zoster infection, herpetic myelitis, keratitis and corneal pigmentation Laminitis, cytomegalovirus pneumonia.
3. Vidarabine antiarrhythmic drugs can convert paroxysmal supraventricular tachycardia into sinus rhythm. Used for supraventricular arrhythmias associated with the atrioventricular.
4. In the pharmaceutical industry, Vidarabine is mainly used in the manufacture of adenosine; adenosine triphosphate; coenzyme and its series of products such as cyclic adenosine monophosphate.
5. Vidarabine treatment of angina pectoris, myocardial infarction, coronary insufficiency, arteriosclerosis, essential hypertension, cerebrovascular disease, stroke sequelae, progressive muscle atrophy. Patients with atrioventricular block and acute myocardial infarction are banned.
